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Endocrine disruptors mimic natural
hormones, thereby causing various effects
or damage in humans and other animals.
Estrogenic compounds are a particularly
serious problem because their effects can be
transferred to children through damage to
the female reproductive organs in the
mothers. The effects of estrogenic com-
pounds ﬁrst appear in the estrogen-respon-
sive genes that include estrogen receptors
(ERs), followed by changing expression lev-
els of many other genes and resulting in
cellular responses that appear as various
symptoms (McDonnell and Norris 2002).
As we identify more signaling pathways
within the cell, we become aware of more
cases in which common pathways are used
for different signalings. Dioxin, for exam-
ple, has an effect through the aryl hydro-
carbon receptor, which to some degree may
share common cascades with the ER path-
way [Carlson and Perdew 2002; reviewed
by Safe (2001)]. Therefore, unraveling sig-
naling pathways will provide clues not only
to the estrogen signaling pathway alone but
also to other pathways.
Estrogenic chemicals can act upon the
cell through two major pathways: a) direct
interaction with the ERs and b) interactions
with other molecules ﬁrst. As estrogen binds
to ERs more tightly than to other molecules,
the major effects originate from the first
pathway. However, when the chemical has
low estrogen activity and the activity of
other interactions is high, estrogen activity
can be masked or disguised by the second
pathway. Furthermore, the major estrogen
activity is not conducted by a unique path-
way. First, there are at least two types of
ERs, ER-α (Green et al. 1986) and ER-β
(Kuiper et al. 1996), which differ in their
affinity for ligands and the way in which
they transduce signals (Katzenellenbogen
and Katzenellenbogen 2000). Differences in
affinity between  ER-α and ER-β were
reported for methoxychlor and its analog
DDT (Jacobs et al. 2003). As for the  ER-α,
tamoxifen is an antagonist against natural
estrogen but has agonist activity in the
uterus, whereas ICI 182,780, a well-known
pure antagonist, does not show such activity
(Branham et al. 1996). This difference can
be explained by the difference in the ligand-
dependent or -independent activation func-
tions assisted by coactivators and has been
observed in other chemicals [reviewed by
McDonnell et al. (2002); McKenna and
O’Malley (2002)]. This indicates that, even
for the ﬁrst pathway, using any one of these
signaling pathways as an indicator of estro-
gen activity would be biased and specific
signals could be enhanced, resulting in
differences between the expected and real
biological outcomes.
The second pathway is more complex.
It may include various metabolic and
modification pathways for chemicals, and
estrogen activity could be higher or lower
than the original, depending on the products
(Beresford et al. 2000). Methoxychlor, for
example, is metabolized to mono- and
bisphenolic forms by oxygenase (Bulger
et al. 1978) or by cytochrome P450 iso-
forms (Hu and Kupfer 2002). These
metabolites have more estrogen activity
than methoxychlor. Such a metabolic acti-
vation of estrogenic chemicals was also
reported for bisphenol A and bisphenol B
(Yoshihara et al. 2001), 2-nitrofluorene
(Fujimoto et al. 2003), and styrenes
(Kitamura et al. 2003). Metabolic inactiva-
tion or inactivation by modification could
also occur in many chemicals. As estrogen
activity results in growth and proliferation
of the cell through the activity of transduc-
ing signals by means of hormones, growth
factors, cytokines, and others, monitoring
estrogen activity at the steps close to such
cellular responses rather than at the begin-
ning (receptor binding, for example) is cru-
cial for reliable evaluation of estrogenicity.
Previously we found that a significant
number of genes responded to estrogen in a
DNA microarray analysis and we character-
ized some of them, including solute carrier
family 7, member 5 (SLC7A5), retinoblas-
toma-binding protein 8 (RBBP8), and
c-myc promoter-binding protein 1 (IRLB)
(Inoue et al. 2002b). We also found that
many of these genes responded to estrogen
in a manner similar to that in cancer cells
from the breast, ovary, stomach, kidney,
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We developed a DNA microarray to evaluate the estrogen activity of natural estrogens and
industrial chemicals. Using MCF-7 cells, we conducted a comprehensive analysis of estrogen-
responsive genes among approximately 20,000 human genes. On the basis of reproducible and
reliable responses of the genes to estrogen, we selected 172 genes to be used for developing a cus-
tomized DNA microarray. Using this DNA microarray, we examined estrogen activity among
natural estrogens (17β-estradiol, estriol, estrone, genistein), industrial chemicals (diethyl-
stilbestrol, bisphenol A, nonylphenol, methoxychlor), and dioxin. We obtained results identical to
those for other bioassays that are used for detecting estrogen activity. On the basis of statistical
correlations analysis, these bioassays have shown more sensitivity for dioxin and methoxychlor.
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Toxicogenomics Articleand other sites. Here, using a customized
DNA microarray with newly selected estro-
gen-responsive genes, we outline an experi-
mental system with more sensitivity for
evaluation of estrogen activity in natural
and industrial chemicals on the basis of sta-
tistical analysis of gene response. Our goal is
to establish an experimental system with
more sensitivity for the evaluation of estro-
gen activity in these chemicals, which can
be applied even to those having low activity.
Materials and Methods
Cell Culture and Materials
MCF-7 cells were obtained from JCRB Cell
Bank (National Institute of Health Sciences,
Tokyo, Japan) and cultured in RPMI 1640
medium supplemented with 10% fetal
bovine serum (FBS) at 37°C under 5% car-
bon dioxide. Cells were cultured in phenol
red-free RPMI 1640 medium with 10%
FBS treated with dextran-coated charcoal
for 3 days and treated with ethanol (vehicle)
or a variety of chemicals for 72 hr.
17β-Estradiol (E2), estriol, estrone, genis-
tein, diethylstilbestrol (DES), bisphenol A,
nonylphenol, and methoxychlor were
obtained from Sigma–Aldrich (St. Louis,
MO, USA) and used at the concentrations
of 10 nM (E2, estriol, estrone, DES) or
10 µM (genistein, bisphenol A, nonylphe-
nol, and methoxychlor). Dioxin (2,3,7,8-
tetrachlorodibenzo-p-dioxin; purity 99.0%)
was obtained from Cambridge Isotope
Laboratories (Andover, MA, USA) and
used at a concentration of 50 mg/mL in
dimethyl sulfoxide.
cDNA Microarray Analysis
GeneChip analysis was conducted using
human U95A oligonucleotide probe arrays
(Affymetrix, Santa Clara, CA, USA)
according to the supplier’s protocols, as fol-
lows. Total RNA (1 µg) was used to gener-
ate a cRNA probe by T7-transcription.
The fragmented cRNA (10 µg) was
hybridized to the microarrays in 200 µL of
a hybridization cocktail by incubation at
45°C for 16 hr in a rotisserie oven set at
60 rpm. The microarrays were then washed
with a nonstringent wash buffer [6×
NaCl/NaH2PO4/EDTA (SSPE)] at 25°C,
followed by a stringent wash buffer
[100 mM MES (pH 6.7), 0.1 M NaCl, and
0.01% Tween 20] at 50°C. The microar-
rays were stained with streptavidin phyco-
erythrin (Molecular Probes, Eugene, OR,
USA), washed again with 6× SSPE, stained
with biotinylated antistreptavidin IgG fol-
lowed by streptavidin phycoerythrin, and
washed a third time with 6× SSPE. The
arrays were scanned using a GeneArray
scanner (Affymetrix) at a resolution of
3µ m, and the scanned image was quantita-
tively analyzed with Microarray Suite 4.0
(Affymetrix). For normalizing the data to
compare mRNA expression levels among
samples, we unified the values to 1,000 as
an average of average difference scores cor-
responding to the signal intensities of all
probe sets in each sample. 
Microarray analysis using Incyte-
Genomics (Palo Alto, CA, USA) micro-
arrays was performed as reported previously
(Inoue et al. 2002b).
A custom cDNA microarray (EstrArray)
was manufactured by InfoGenes Co., Ltd.
(Tsukuba, Japan) by mechanical spotting of
cDNA (∼500 bp  to ∼1.5 kb) of the genes
selected from the above DNA microarray
assays [see Inoue et al. (2002b) for details].
The analysis using EstrArrays was per-
formed as follows: After the cells were cul-
tured for 72 hr in the presence of chemicals
at indicated concentrations, mRNA was
puriﬁed using the PolyATract System 1000
(Promega, Madison, WI, USA) according
to manufacturer instructions. The quality of
mRNA was confirmed by examining
the optical density and also by reverse
transcription–polymerase chain reaction
(RT–PCR) assay for several marker genes
(β-actin for all, and pS2 and ER-α for the
chemicals with high estrogen activity). Each
mRNA was labeled with fluorescent
Cyanine 3 (Cy3)-dUTP (for the treatment
of chemicals) or Cy5-dUTP (for the con-
trol) at 37°C for 1.5 hr using SuperScript II
(Invitrogen, Carlsbad, CA, USA) and ran-
dom primers (a mixture of 6 mers and
9 mers). Both Cy3- and Cy5-labeled probes
were mixed and denatured under alkaline
conditions for 1 hr. After free fluorescent
nucleotides were removed using Microcon-30
columns (Millipore, Bedford, MA, USA),
probes were hybridized to EstrArrays
for 16 hr in 5× NaCl/Na citrate (SSC)
and 0.5% sodium dodecyl sulfate at
65°C. After hybridization, slides were
washed twice with 0.05× SSC for 5 min at
room temperature. The ﬂuorescent intensi-
ties were scanned with a ChipReader
(Virtek, Waterloo, Ontario, Canada), and
scanned images were analyzed using IPLab
(Scanalytics, Fairfax, VA, USA) according
to manufacturer instructions. The ratio
(Cy3/Cy5) was calculated for each spot,
and after transforming the ratio into a loga-
rithmic value (log2), the value was normal-
ized using internal control genes. Clustering
analysis was performed using the Cluster
program and the results were displayed with
the TreeView program [for both programs
see Eisen et al. (1998)]. The genes spotted
on EstrArray or GenBank accession num-
bers (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=nucleotide)] were as follows:
ACO2, ADORA2A, AGTR1, AIM1,
AKR1C4, APPL, AR (AREG), ARHGDIA,
ARNT2, ASNS, ASS, ATF3, BF, BRCA1,
CAMK2A, CAPNS1, CBX1, CCNA1,
CCR2, CDC14, CDC6, CDH18, CDIPT,
CDKN1A, CDSN, CEBPB, CLIC4,
CPT1A, CtIP (RBBP8), CTNND2, CTSD,
D53 (TPB52L1), DAZAP2, DDEF,
DHCR24, DHX29, EDN2, EFEMP1,
EGR3, EIF3 (EIF3S9), ENO2, ENO3,
FBP1, FOS, FRA2, FTH1, FUT8, GARS,
GFPT1, GOT1, gp96 (TRA1), GRP78
(HSPA5), GUCA2B, H3F3B, HAX1,
HDAC6, HMMR, HSP70, IEX-1 (IER3),
IFRD1, IGFBP4, IGFBP5, IL1R1, IL-2RB,
ILK, IMP4, ISG20, JUN, KRT16, KRT8,
LAMP3, LCN2, LGALS3BP, MAL,
MAN1A1, MAP1, MATN2, MBP-1
(IRLB), MGP, MIC1, MTHFD2,
NCKAP1, NPY1R, PACE4, PCK2,
PCYT1A, PDZK1, PEG10, PHGDH,
PI3KC3, PIG11, PMAIP1, PMP22,
PMPCA, PRKCD, PRKCSH, PSAT1,
PTPN18, PVR, QSCN6, RACGAP1,
RAP1GAP, RCN1, RDH11, RHOC,
RIP140, RSK, RUNX1, S100P, SCD,
SECTM1, SELENBP1, SERPINA, SFTPB,
SH3BGR, SH3BP5, SHMT2, SLC12A2,
SLC1A4, SLC1A5, SLC26A3, SLC7A11,
SLC7A5, SORD, STC2, SYNGR2, TAC-
STD2, TAF9, TCN1, TFII-I (GIF2I),
TFIIS (TCEA1), TIEG, TM4SF1, TRB3,
TSPAN-1, U5-116KD, ULK1, VAMP5,
WARS, XPOT, YARS, ZNF231, and
expressed sequence tags (ESTs) (L05367,
NM_052965, AL109840, XM097954,
NM_017867, NM_017867, NM_014846,
NM_173481, and NM_024092), along
with the expression markers AHR, CCND1,
CYP19A1, CYP1A1, ERBB2, ESR1, ESR2,
HSD17B2, NCOA1, NCOA3, PGR, STS,
and TFF1, and the calibration markers
ACTB, ACTN1, CPEB2, FLJ12748,
FUSIP1, G0S2, G6PD, GCLM, GTF2H2,
HNRPK, IL6ST, KANK, KIAA0349,
KRT6E, LOC129401, NAV1, NMA,
NPM1, PAK4, PRKCD, RPL35, SDR1,
SLC25A16, SLC29A2, SOCS2, TNFRSF7,
and ZNF147. Different parts of the same
gene or cDNA were used for some genes
(a total of 12 genes), giving multiple plots
in the figures. The expression markers are
the marker genes for estrogen [all except
cytochrome P450 1A1(CYP1A1)] or dioxin
(CYP1A1) responses, and the calibration
markers are the genes for adjusting the sig-
nals between Cy3 and Cy5 labels (therefore
they are not estrogen responsive).
Real-Time Quantitative RT-PCR
mRNA was isolated using a PolyATract
System 1000 (Promega) as described
previously. The first-strand cDNA was
synthesized from 200 ng mRNA using
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PCR was carried out using a LightCycler-
FastStart DNA Master SYBR Green I
kit (Roche Molecular Biochemicals,
Mannheim, Germany). The PCR condi-
tions were as follows: denaturation at 95°C
for 1 min, followed by 40 cycles of denatu-
ration at 94°C for 10 sec, annealing at
57°C for 5 sec, and extension at 72°C for
20 sec. After PCR a melting curve was con-
structed by increasing the temperature
from 72 to 95°C. The product was
resolved in agarose gels to ensure that the
correct product was amplified in the reac-
tion. PCR was repeated 3 times for each
gene, and the average and standard devia-
tions were calculated. The PCR primers
were as follows: SLC7A11, 5´-ACAGTG
CCAGAGTGAAGAAACTC-3´ and
5´-CCAGCTAAATCCCTAACTT
GGAT-3´; EGR3, 5´-CCATGATTCCTG
ACTACAACCTC-3´ and 5´-GTGGAT
CTGCTTGTCTTTGAATG-3´; PDZK1,
5´-CCTTTCTCAAGGAATGAG
TTGTG-3´ and 5´-CCGCCTGTAAGA
CAAATGATAAC-3´; S100P, 5´-GTAC
TTTGAGAAGGCAGGACTCA-3´ and
5´-GGAATAATTGCCAACAAACACTT-
3´; AR, 5´-AAACAAGACGGAAAGT
GAAA-3´ and 5´-TTACCTTCGTGCAC
CTTTAT-3´; WARS, 5´- AGGCATCT
TCTTCTCACACAGAG-3´and 5´- GAT
ACTTCTCGTCATCCGTCATC-3´;
SELENBP1, 5´-GAAGGTACATGGT
CAGTGGAGAA-3´ and 5´-GAGATGTC
ATACTGCCTCAGGTC-3´; ENO2, 5´-
GCACTTTCCACTTCTTCCTTTCT-3´
and 5´-AAGTGACACATGGTCCCT
CTCTA-3´; ARHGDIA, 5´-CCTCACTA
GCCTCTACTCCCTGT-3´ and 5´-
ACTGAGGTGACTTGAGTGTTGG-3´;
AGTR1, 5´-CTGAATAACTCACTG
ATGCCATCCCAG-3´ and 5´-GCCAGC
AGCCAAATGATGATGCAGGTG-3´;
IGFBP5, 5´-ATGGATTTGAGAGGAAA
GAGAGG-3´ and 5´-AGCACCCTCC
TAAGGTTACTCAC-3´; and SLC12A2,
5´-GAGGAAATCATTGAGCCAT
ACAG-3´ and 5´-GAGCACTAGACACA
GCACCTTTT-3´.
Results
We first screened the estrogen-responsive
genes in a human mammary tumor cell
line, MCF-7, using two different com-
prehensive DNA microarray systems,
UniGem, version 2 (IncyteGenomics) con-
taining 9,182 genes and GeneChip U95A
(Affymetrix) containing 12,625 genes
(Figure 1). Approximately 300 genes in
UniGem,  and 850 genes in GeneChip
U95A showed a response higher than
2-fold and 3-fold, respectively. To examine
the response to estrogen by monitoring
transcription of the genes, we selected
172 genes after the reproducibility of their
upregulation or downregulation on estro-
gen treatment (10 nM E2 for 3 days) was
confirmed by repeated DNA microarray
and/or RT–PCR analyses (Inoue et al.
2002b; also, data not shown). To confirm
that the data obtained were reliable for the
genes with various expression levels, we
arbitrarily divided the genes into high- and
low-expression types. The genes categorized
as the high expression type characterized by
abundant transcript are summarized in
Table 1. These genes had transcripts with
expression levels higher than those of the
solute carrier family gene 2, member 1
(SLC2A1) and the keratin 6B gene in each
DNA microarray analysis (both appeared
in both DNA microarrays and showed
identical expression levels), and included
the genes for amino acid transporters, and
structural, ion-related, translation-, tran-
scription-, and cell cycle–associated pro-
teins. The expression of most of the tRNA
synthetase genes and genes for the TATA-
box binding protein–associated factor and
histone deacetylase was probably upregu-
lated for enhancing protein synthesis or
transcription, respectively. Meanwhile, the
genes associated with specific tissues, such
as those for the nervous system, showed
downregulation. A similar analysis was per-
formed for the genes categorized as the low
expression type (Table 2). Upregulation of
the genes related to various synthetases,
transcription-related, and cell cycle or
growth-associated proteins as well as recep-
tors and ion or amino acid transporters was
also prominent in this type. Among the
tumor-associated genes, oncogenic genes
such as for c-fos, AML (acute myeloid
leukemia) 1b, FOS-like antigen 2, and a
v-jun homolog were upregulated, whereas
tumor suppressor–related genes (absent in
melanoma 1) (Ray et al. 1996) were
slightly downregulated. Expression of the
ER-α gene was downregulated as observed
for progressive breast tumors (Lapidus et al.
1998; Yoshida et al. 2000).
On the basis of the information
obtained from the estrogen-responsive
genes shown above, we constructed a cus-
tomized DNA microarray, EstrArray, that
contains 203 genes, including genes show-
ing either upregulation (108 genes) or
downregulation (64 genes) in their expres-
sion. EstrArray also contains calibration
markers for adjusting the ﬂuorescent levels
between Cy3- and Cy5-labeled cDNAs
(28 genes) and expression markers such as
the genes for trefoil factor, the ER-α and
ER-β, steroid sulfatase, and other estrogen-
related proteins (14 genes, 11 showing
estrogen responsiveness, resulting in a total
of 203 genes).
We used this microarray system to ana-
lyze natural estrogens and industrial chemi-
cals (Figures 2, 3). First, we examined the
reproducibility of the assay by repeating
the analysis using E2 twice (E2 and E2-2),
which resulted in very similar profiles
(Figure 2) and gave a high correlation coef-
ﬁcient (R = 0.928) (Figure 3A). When the
reproducibility was examined for the genes
of the high and low expression types sepa-
rately as examined in Tables 1 and 2, the
high expression type showed a higher score
(R = 0.935) (Figure 3C) than the total gene
score. Moreover, the low-expression type
also showed a relatively high score (R =
0.910) (Figure 3B), suggesting a high
reproducibility even for the low-expression
type. Cluster analysis indicated that very
similar profiles were obtained among the
chemicals already known to have estrogen
activity (10 nM E2, 10 nM DES, 10 µM
nonylphenol, 10 nM estriol, 10 µM genis-
tein, and 10 nM estrone) (Figure 2). Other
Toxicogenomics | Evaluating estrogen activity using a customized DNA microarray
Environmental Health Perspectives • VOLUME 112 | NUMBER 7 | May 2004 775
300
250
200
150
100
50
0
E2–
E
2
+
E
2
+
E2–
120,000
100,000
80,000
60,000
40,000
20,000
0
A B
20,000 40,000 60,000 80,000 100,000 120,000 0 150 200 250 300 05 0 100
Figure 1. Expression proﬁling of the human genes using DNA microarrays. The response to 10 nM E2 was
examined with comprehensive sets of human genes on (A) UniGem, version 2 (IncyteGenomics) and
(B) GeneChip U95A (Affymetrix). Each contains a total of 9,182 and 12,625 genes, respectively. The vertical
and horizontal axes are indicated by arbitrary units derived from ﬂuorescent intensities.Toxicogenomics | Terasaka et al.
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Table 1. The high expression type in the estrogen-responsive genes.a,b
Amino acid transporters
5.3 Solute carrier family 7 (SLC7A5)
2.4 Solute carrier family 1 (SLC1A5)
Calcium and other ion related
2.9 Ferritin (FTH1)
2.0 Reticulocalbin 1 (RCN1)
–2.8 Calpain, small polypeptide (CAPN2, CAPNS1)
Binding proteins
2.7 SH3-domain binding protein (SH3BP5)
2.1 Inhibitor of DNA binding 4 (ID4)
2.0 HS1 binding protein (HAX1)
Receptors
2.0 Poliovirus receptor (PVR)
Tumor-associated proteins
3.3 Tumor rejection antigen (TRA1)
3.1 FOS-like antigen (FOSL2)
2.5 Pituitary tumor-transforming (PTTG1) 
–2.1 Ras homolog gene family, member C (ARHC) 
–2.6 c-myc promoter-binding protein (IRLB)
Synthetases, transferases, kinases, or others
3.9 Methylene tetrahydrofolate dehydrogenase (MTHFD2)
2.9 Argininosuccinate synthetase (ASS)
2.7 Alpha-1-antichymotrypsin (SERPINA)
2.4 Cathepsin D (CTSD)
2.2 Serine hydroxymethyltransferase 2 (SHMT2)
2.1 Mannosidase alpha (MAN1A1)
2.0 Protein geranylgeranyltransferase type I (PGGT1B)
–2.0 Phosphatidylinositol synthase (CDIPT)
–2.2 Sorbitol dehydrogenase (SORD)
–2.3 Aconitase 2, mitochondrial (ACO2)
–2.6 Carnitine palmitoyltransferase (CPT1A)
–2.6 Fructose-bisphosphatase (FBP1)
–3.7 Isocitrate dehydrogenase, mitochondrial (IDH2)
Nervous system–related proteins
–2.0 Protein tyrosine phosphatase (PTPN18)
–2.3 Synaptogyrin (SYNGR2)
–2.7 Enolase gamma, neuronal (ENO2)
Translation-associated proteins
5.7 Tryptophanyl-tRNA synthetase (WARS)
3.5 Alanyl-tRNA synthetase (AARS)
3.1 Glycyl-tRNA synthetase (GARS)
2.9 Tyrosyl-tRNA synthetase (YARS)
2.0 Isoleucine-tRNA synthetase (IARS)
–2.2 Eukaryotic translation initiation factor, subunit 9 (EIF3S9)
Transcription-associated proteins
2.1 TATA box binding protein-associated factor (TAF9)
2.0 Histone deacetylase (HDAC6)
–2.6 GATA-binding protein 3 (GATA3)
–2.8 General transcription factor IIi, pseudogene 1(GTF2I)
Cell cycle or growth-associated proteins
2.0 CDC6 homolog (CDC6)
–2.0 Mal, T-cell differentiation protein (MAL)
–2.2 Protein kinase C substrate 80K-H (PRKCSH)
–2.9 Protein kinase C delta (PRKCD)
Cellular responsive proteins 
4.9 Heat shock 70kDa protein 5 (HSPA5)
–3.6 Heat shock 70kDa protein 1 (HSP70)
–3.4 Clusterin (CLU)
Structural proteins
2.8 H3 histone, family 3B (H3F3B)
2.2 Keratin 8 (KRT8)
–2.0 Membrane component, surface marker 1 (M1S1)
aFold increases or decreases (in negative values) are shown. bGene names are either
from UniGene (htttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) or they are
the conventional names. For the latter, the UniGene names are in parentheses upon ﬁrst
mention.
Table 2. The low-expression type in the estrogen-responsive genes.a,b
Receptors
6.2 Transcobalamin I (TCN1) 
3.0 Nuclear receptor interacting protein 1 (RIP140)
3.0 Exportin, tRNA (XPOT)
–3.0 Estrogen receptor 1 (ESR1)
Calcium and other ion-associated proteins
5.5 Stanniocalcin (STC2)
5.1 S100 calcium-binding protein A9 (S100A9) 
4.7 S100 calcium-binding protein P (S100P)
–3.7 Cadherin 18 (CDH18)
Amino acid transporters 
5.5 Solute carrier family 1, member 4 (SLC1A4)
4.3 Solute carrier family 12, member 2 (SLC12A2)
Membrane proteins
3.6 Semaphorin 3B (SEMA3B)
3.5 Hyaluronan-mediated motility receptor (HMMR)
Binding proteins
–4.4 Selenium-binding protein 1 (SELENBP1)
Estrogen-associated proteins
11.7 Trefoil factor 1 (TFF1)
8.1 Tumor protein D52-like 1 (TPD52L1)
Oncogene-associated proteins
5.1 FOS-like antigen 2 (FRA2)
3.0 v-jun avian sarcoma virus 17 oncogene homolog (JUN)
7.5 c-fos (FOS)
14.4 AML1b (RUNX1)
Tumor-associated proteins
4.2 Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)
4.0 Interferon-stimulated gene (ISG20)
4.0 Downregulated in adenoma (SLC26A3)
3.9 Retinoblastoma-binding protein 8 (RBBP8)
–3.1 Absent in melanoma 1 (AIM1)
Nervous system–related proteins
8.2 Amphiregulin (AREG) 
3.2 Neuropeptide Y receptor Y1 (NPY1R)
–3.0 Bassoon (BSN) 
–3.2 Catenin (cadherin-associated protein), delta 2 (CTNND2)
Synthetases, transferases, kinases, or others
12.1 Asparagine synthetase (ASNS)
7.6 Phosphoenolpyruvate carboxykinase 2 (PCK2)
6.3 EST, highly similar to phosphoserine aminotranferase
3.9 Glutamic-oxaloacetic transaminase 1, soluble  (GOT1)
3.8 Phosphoinositide-3-kinase, class 3 (PI3KC3)
3.6 Unc-51 (C. elegans)-like kinase 1 (ULK1)
3.6 Aldo-keto reductase family 1, member C4 (AKR1C4)
3.2 Glutamine-fructose-6-phosphate transaminase 1 (GFPT1)
3.1 Ribosomal protein S6 kinase, 90 kDa (RSK)
–3.2 Fucosyltransferase 8 (FUT8)
–3.3 Enolase 3 (ENO3) 
–3.5 Paired basic amino acid cleaving system 4 (PACE4)
Transcription related
5.1 CCAAT/enhancer binding protein (C/EBP), beta (CEBPB)
4.9 Activating transcription factor 3 (ATF3)
4.3 Motilin (MLN)
Cell cycle or growth-associated proteins
5.0 Prostate differentiation factor (PLAB, MIC1)
3.5 Insulin-like growth factor-binding protein 4  (IGFBP4)
3.4 TGFβ inducible early growth response (TIEG)
3.4 Cyclin A1 (CCNA1)
3.2 B-factor, properdin (BF)
–6.7 EGF-containing ﬁbulin-like extracellular matrix protein 1 (EFEMP1)
–7.0 Insulin-like growth factor binding protein 5 (IGFBP5)
–12.8 Insulin-like growth factor binding protein 5 (IGFBP5) 
Cellular responsive proteins
8.8 Early growth response 3 (EGR3)
Structural proteins
8.2 Matrix Gla protein (MGP)
3.9 Microtubule-associated protein 1B (MAP1)
aFold increases or decreases (in negative values) are shown.  bGene names are either
from UniGene (htttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=unigene) or they are
the conventional names. For the latter, the UniGene names are in parentheses upon ﬁrst
mention.chemicals showed relatively high correlation
coefficients (0.929 for estriol, 0.847
for estrone, 0.692 for DES, 0.909 for
genistein, and 0.862 for nonylphenol)
Figure 3D–H). Relatively low scores for
estrone and DES can be explained by the
low response of the genes when they were
assayed at the concentration of 10 nM.
Bisphenol A and methoxychlor, on the
other hand, showed similar but clear differ-
ences (0.651 for bisphenol A and 0.556 for
methoxychlor) (Figure 3I–J). Dioxin
(2,3,7,8-tetrachlorodibenzo-p-dioxin;
10 nM), in contrast, showed a very differ-
ent profile, partly because most genes did
not respond well, and naturally showed a
very low score (R = 0.213) (Figure 3K). A
dioxin marker, CYP1A1, responded well.
The response of a total of 12 genes
(6 showing upregulation and 6 showing
downregulation) to E2 and other chemicals
is summarized in Figure 4A. For example,
amphiregulin (AR) showed a relatively high
response to E2 (5.4-fold increase). The
response to the other chemicals with rela-
tively high estrogen activity (estriol,
estrone, DES) was distinguishable although
low (1.6- to 1.9-fold increases). The chem-
icals with low estrogen activity, however,
showed a relatively high response when
their concentrations were increased to
10 µM. Expression of the AT1 receptor
gene (AGTR1)  was downregulated by the
treatment with E2 (2.8-fold decrease) and
all other chemicals (1.2- to 6.4-fold). We
next examined the response of the genes to
E2 by the real-time PCR (Figure 4B). The
degrees of response were generally higher
for the real-time PCR because of higher
backgrounds in DNA microarray assay.
However, the response was confirmed by
both methods.
Discussion
Customized DNA Microarray
DNA microarray technology is one of the
most potentially powerful tools in modern
toxicogenomics because it can shorten the
time for elucidating toxicological pheno-
types and widen the way for drug discovery
(Inoue 2003). However, determining the
relationship between specific gene expres-
sion profiles and toxicological phenotypes
will be accelerated by the development of
customized DNA microarrays, the accumu-
lation of proﬁles speciﬁc to chemicals, and
an increase in the knowledge of gene func-
tions (Adachi et al. 2002; Inoue et al. 2002a;
Watanabe et al. 2002; Wong et al. 2003).
Here we developed a customized DNA
microarray, EstrArray, for expression proﬁl-
ing of estrogen-responsive genes. EstrArray
contains 172 estrogen-responsive genes
Toxicogenomics | Evaluating estrogen activity using a customized DNA microarray
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Figure 2. Clustering of gene expression after the treatment of various estrogens and industrial chemicals
examined using EstrArrays. E2-2, E2 twice. Gene expression proﬁles were obtained after treatment with
10 nM of E2, estrone, estriol, and DES, 10 µM nonylphenol, bisphenol A, genistein, and methoxychlor, or
50 µg/mL dioxin. The results of EstrArray analysis are shown as values of log2 (ﬂuorescent intensity for
chemical plus/ﬂuorescent intensity for chemical minus), which were colored according to the color scale.selected from approximately 20,000 genes,
almost half the estimated number in the
whole human genome. As approximately
95% of the genes examined did not
respond to estrogen or were not expressed
in MCF-7 cells, the genes used for
EstrArray were considered to represent the
genes most suitable for monitoring estrogen
responsiveness. As we reported previously,
some of these genes were characterized
extensively to show reproducible estrogen
responsiveness by Northern blot analysis
(Inoue et al. 2002b) and to examine their
potential functions (data not shown).
EstrArray also contains marker genes for
the calibration of fluorescent levels that
cover a wide range of expression levels for
normalizing signals between the presence
and absence of chemicals. The genes,
which show estrogen responsiveness, can be
classified into several types according to
their function (Tables 1 and 2; summarized
in Figure 5). Among the genes related to
tumor-associated genes, oncogenes and
tumor-promoting genes are generally
upregulated, whereas the genes related to
tumor suppression and the ER-α gene are
downregulated. This is consistent with the
effects of estrogen, namely, the promotion
of tumorigenesis. For growth- and ion-
associated genes and other genes, the
expression of various transporters, syn-
thetases, transcription factors, growth
response genes, and structural genes was
upregulated, indicating enhancement of
growth and proliferation of the cell.
Meanwhile, the genes related to specific
differentiation of the cell, such as those for
neuronal proteins, were downregulated.
Genes Responding to Estrogenic
Chemicals
Among the estrogen-responsive genes used
for EstrArray, the AR and AGTR1 were
examined in detail (Figure 4). Both showed
a relatively high response to E2 (5.4-fold
increase for AR and 2.8-fold decrease for
the AGTR1) and a similar tendency of
response to the other chemicals examined
here. Estrogen responsiveness was low for
estriol, estrone, and DES compared with E2
when they were examined at the concentra-
tion of 10 nM, except for the  AGTR1 with
estriol. These data and the result of the sta-
tistical correlation study (Figure 3) indicate
that the genes responded to most chemicals
analyzed here in similar ways and suggest
that these genes commonly respond to
estrogen activity. The difference in the
degree of response for each gene, however,
might be due to the difference in biological
effects originating from structural differ-
ences. This difference is particularly impor-
tant for the evaluation of estrogen activity,
Toxicogenomics | Terasaka et al.
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Figure 3. Estrogenicity of chemicals examined using EstrArrays. E2-2, E2 twice. Gene expression proﬁles of
estrogen-responsive genes were compared between the independent E2 treatments and shown in a scat-
terplot graph (A). The same comparison was performed for the genes of the (B) low-expression or (C) high-
expression types. Gene expression proﬁles were compared between (D) E2 and estriol, (E) estrone, (F) DES,
(G) genistein, (H) nonylphenol, (I) bisphenol A, (J) methoxychlor, and (K) dioxin. The axes are shown in log2
(fluorescent intensity for chemical plus/fluorescent intensity for chemical minus) calculated for each
chemical. The correlation coefﬁcient (R) between two proﬁles was calculated for each graph  on the basis
of linear regression between the two proﬁles. CYP1A1, a dioxin marker, is indicated in K.especially when the activity is low, giving an
advantage to this assay (discussed below).
The functional relationship of these
genes to estrogen signaling is mostly
unknown. AR is an epidermal growth factor
and is expressed in invasive mammary
tumors together with its receptor, forming a
potential autocrine loop for tumor progres-
sion (Ma et al. 2001). AR is also a target
gene for vitamin D3 (Akutsu et al. 2001)
and progesterone (Das et al. 1995) and may
go through the ErbB pathway for oncogenic
activity by inhibiting apoptosis (Hurbin
et al. 2002). Therefore, activation of the AR
gene may well explain the progression of
estrogen-independent breast cancer. The
AGTR1 is a type 1-angiotensin II receptor
whose expression is downregulated by
estrogen in several tissues. This explains the
estrogen deficiency in hypertension and
other diseases (Krishnamurthi et al. 1999;
Nickenig et al. 1998), although the expla-
nation at the molecular signaling level is
not so clear. The pathways common to the
epidermal growth factor receptor or the
insulin-like growth factor could be poten-
tial signaling mechanisms (Touyz and
Berry 2002).
Evaluating Estrogenicity with
EstrArray
The chemicals used here have estrogen
activity in reporter gene assays (Demirpence
et al. 1993; Gaido et al. 1999; Inoue 
et al. 2002a; Pons et al. 1990) and cell
proliferation/uterotrophic assays [reviewed
by Kanno et al. (2003)] and upregulate
estrogen target genes in responsive cells
(Nagel et al. 2001; Vivacqua et al. 2003).
Dioxin does not have estrogen agonist
activity (Astroff and Safe 1988; Spink et al.
1990). Cluster analysis shown in Figure 2
clearly demonstrated similar expression pro-
ﬁles among estrogenic chemicals, E2, estriol,
estrone, genistein, nonylphenol, and DES.
Note that the data were obtained for 10 µM
in the case of genistein, nonylphenol, and
bisphenol A, whereas a concentration of
10 nM was used for the others. Bisphenol A
at 10 µM showed less of a tendency to
enhance the gene response, although it may
show a higher tendency when examined at a
higher concentration. Methoxychlor at
10 µM showed an even lower response but
showed a meaningful correlation with the
proﬁle for E2. Dioxin, as expected, was clas-
sified as the most distant chemical in the
clustering here.
The evaluation of the estrogenicity of
chemicals used here is unique. First, the
estrogenicity of chemicals was compared as
expression profiles of estrogen-responsive
genes, giving multiple scales provided by
the expression of each gene used here
Toxicogenomics | Evaluating estrogen activity using a customized DNA microarray
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Figure 4. Expression proﬁles of the genes showing upregulation or downregulation in response to estro-
gen and estrogenic chemicals. (A) Responses to various chemicals analyzed using EstrArrays. The verti-
cal axis marked as log2 (C+/C–) indicates log2 (ﬂuorescent intensity for chemical plus/ﬂuorescent intensity
for chemical minus) calculated for each chemical. (B) The response to E2 examined by real-time quantita-
tive RT-PCR. The assays were repeated 3 times and the average and the SD (bracketed) in the log2 values
are shown. The genes examined  are SLC7A11 (solute carrier family 7, member 11), EGR3 (early growth
response 3), PDZK1 (PDZ domain–containing protein), S100P (S100 calcium-binding protein P), AR
(amphiregulin), WARS (tryptophanyl-tRNA synthetase), SELENBP1 (selenium binding protein 1), ENO2
(enolase 2), ARHGDIA (Rho GDP dissociation inhibitor alpha), AGTR1 (angiotensin II receptor type 1),
IGFBP5 (insulin-like growth factor binding protein 5), and SLC12A2 (solute carrier family 12, member 2).compared with the ligand-binding method
and reporter gene assays. This is even
advantageous when the estrogenicity of
chemicals is low, as multiple scales can
give statistically significant evaluations.
The estrogenicity of methoxychlor was not
detected clearly by some assays (Shelby
et al. 1996), but here it showed a distinct
tendency. Second, the estrogenicity shown
here is based on biological effects because
not only the target genes of estrogen/estro-
gen receptor complex but also the genes
that are presumably located downstream of
the estrogen signaling pathway were
included (Inoue et al., in press; Rho et al.
in press). Third, with more information,
the data can be classified according to the
tendency of response among chemicals,
specific to steroids, phenol, and phthalate,
for example, which are expected to have
different effects on the genes. To apply
DNA microarray data for the evaluation of
estrogen activity among various com-
pounds, we are now constructing a data-
base consisting of DNA microarray data of
genes, chemicals, and cells.
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